WebThrough this transaction, we will be acquired by Ipsen and they will be able to expand their oncology footprint and capabilities by integrating our epigenetic expertise and U.S. hematology commercial presence as a result of the acquisition of TAZVERIK, EZM0414, and our preclinical R&D compounds. WebTAZVERIK is a prescription medicine used to treat adults and children aged 16 years and older with epithelioid sarcoma that has spread or grown and cannot be removed by surgery.
Did you know?
WebAug 12, 2024 · Epizyme now operates as ‘an Ipsen company’ at deal close. As part of the transaction, Ipsen acquires Epizyme’s lead medicine, Tazverik ® (tazemetostat), a first-in … WebNov 18, 2024 · Nov. 18, 2024 11:30 UTC. CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced two appointments to the Company’s Board of Directors: clinical oncology executive, Roy A. Beveridge, M.D., and ...
WebJun 27, 2024 · Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology June 26, 2024, 10:00 PM · 20 min read Transaction focused on lead asset Tazverik® (tazemetostat), a …
WebJun 27, 2024 · Under the terms of the agreement and plan of merger, Ipsen, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of Epizyme at a price of $1.45 per share in cash at ... WebAug 23, 2012 · On August 12, 2024, Epizyme was acquired by Ipsen, expanding Ipsen’s oncology portfolio. Epizyme now operates as an Ipsen company. epzy.me/communityguide … Cambridge, MA epizyme.com Joined August 2012 390 Following 2,919 Followers Tweets Tweets & replies Media Likes Pinned Tweet Epizyme @EpizymeRx · Aug 12 @IpsenGroup
WebJun 28, 2024 · Those following along with Epizyme, Inc. ( NASDAQ:EPZM) will no doubt be intrigued by the recent purchase of shares by David Mott, Independent Chairman of the company, who spent a stonking...
WebAug 9, 2024 · Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious … baja ufmgWebIpsen has an agreement in place to acquire oncology specialist Epizyme for $247 million. The primary target in the deal is lymphoma drug Tazverik arakhi appWebJun 27, 2024 · News • Jul 1, 2024. Capital Finance — Ipsen acquires US biotech Epizyme for $247 million. News • Jun 27, 2024. Epizyme, Inc. — Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology. News • Jun 27, 2024. markets.businessinsider.com — Ipsen To Acquire Epizyme For $1.45/share In Cash - Quick Facts. News • Jun 27, 2024. ara khanjianWebJun 27, 2024 · Epizyme ( EPZM) stock is up 65% today on news that the biotech company is being acquired by French pharmaceutical concern Ipsen ( IPSEF ). The deal will see Ipsen … ara khatchadourianWebApr 12, 2024 · STRASBOURG, France, April 12, 2024--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced ... bajau divers documentaryWebJun 27, 2024 · Ipsen to acquire Epizyme, expanding its portfolio in oncology Business Wire June 27, 2024, 1:01 AM · 20 min read Transaction focused on lead asset Tazverik® … bajau divingWebApr 17, 2024 · About Epizyme. Creates drugs to treat patients with genetic predispositions to cancer. The company is currently working on treatments for genetically-linked … bajau facial makeup